Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
View of the Novo Nordisk logo in the company office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little | Reuters
Shares Novo nordisk On Friday, he jumped up on Friday after the Danish pharmaceutical giant announced the positive results of the early stage for the once-weekly amcon-inclination.
The test showed that the treatment carried out by injection led to an average weight loss by 22% in patients with obesity and overweight after 36 weeks. This is compared with weight gain 2.0% among patients receiving placebo over the same period.
Shares at 13.65% at 12:50 pm in London, putting stocks on the rate for the biggest daily profit since August 2023.
Actions of Comrade Addiction Zealand form Also tracked above, last by 4.7%and the ZEPBound manufacturer Eli Lily Abandoned in pre -retrynted trade.
Amcrycutin is aimed at the same intestinal hormone that the vegan mimics, known as the GLP-1, as well as the pancreatic hormone called amilin, which affects hunger. Wegovy is a flagship drug with an obesity novo novo, and Ozempic is his treatment for diabetes.
Amocral
The test was conducted on 125 overweight patients or obese, and the most common side effects were gastrointestinal, and the vast majority were “light and moderate in severity”.
“We are very encouraged by the results of the subcutaneous phase 1b/2a for ameretin in overweight people or obese,” Martin Lange, executive vice -president of Novo Nordisk said in a statement.
“The results observed in the test support the potential of weight loss of this novel Animolecular GLP-1 and agonist of AMILP receptors, Amreatin, which we have previously seen with an oral drug.”
Novo also develops obesity pills. Tests at an early stage Announced in September, showed an average weight loss by 13.1% after 12 weeks. At the time, the company said the treatment was safe and tolerant for patients, but included soft and moderate side effects.
